Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 575

1.

Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms.

Rashid T, Haghighi F, Hasan I, Bassères E, Alam MJ, Sharma SV, Lai D, DuPont HL, Garey KW.

Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01031-19. doi: 10.1128/AAC.01031-19. [Epub ahead of print]

PMID:
31611365
2.

Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule.

Darkoh C, Plants-Paris K, Bishoff D, DuPont HL.

mSystems. 2019 Mar 19;4(2). pii: e00346-18. doi: 10.1128/mSystems.00346-18. eCollection 2019 Mar-Apr.

3.

Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection.

Hibbard J, Jiang ZD, DuPont HL.

Anaerobe. 2019 Apr;56:102-105. doi: 10.1016/j.anaerobe.2019.03.006. Epub 2019 Mar 6.

4.

Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply.

Steffen R, DuPont HL.

J Travel Med. 2019 May 10;26(3). pii: taz014. doi: 10.1093/jtm/taz014. No abstract available.

5.

Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler's diarrhea: a prospective cohort study protocol.

Lindsay L, DuPont HL, Moe CL, Alberer M, Hatz C, Kirby AE, Wu HM, Verstraeten T, Steffen R.

BMC Infect Dis. 2018 Dec 3;18(1):605. doi: 10.1186/s12879-018-3461-6.

6.

Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2019 Jan;25(1):188. doi: 10.1038/s41591-018-0305-2.

PMID:
30479380
7.

Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.

Steffen R, Jiang ZD, Gracias Garcia ML, Araujo P, Stiess M, Nacak T, Greinwald R, DuPont HL.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay116.

8.

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2018 Dec;24(12):1804-1808. doi: 10.1038/s41591-018-0238-9. Epub 2018 Nov 12. Erratum in: Nat Med. 2018 Nov 27;:.

9.

Visualization-assisted binning of metagenome assemblies reveals potential new pathogenic profiles in idiopathic travelers' diarrhea.

Zhu Q, Dupont CL, Jones MB, Pham KM, Jiang ZD, DuPont HL, Highlander SK.

Microbiome. 2018 Nov 8;6(1):201. doi: 10.1186/s40168-018-0579-0.

10.

Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial.

Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson C, Do KA, DuPont HL.

PLoS One. 2018 Nov 2;13(11):e0205064. doi: 10.1371/journal.pone.0205064. eCollection 2018.

11.

Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.

Dogan B, Belcher-Timme HF, Dogan EI, Jiang ZD, DuPont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KW.

FEMS Microbiol Lett. 2018 Nov 1;365(22). doi: 10.1093/femsle/fny249.

PMID:
30299475
12.

Non-O157 Shiga toxin-producing Escherichia coli-A poorly appreciated enteric pathogen: Systematic review.

Valilis E, Ramsey A, Sidiq S, DuPont HL.

Int J Infect Dis. 2018 Nov;76:82-87. doi: 10.1016/j.ijid.2018.09.002. Epub 2018 Sep 14.

13.

Search for the optimal antimicrobial therapy of Clostridium difficile infection.

DuPont HL.

Lancet Infect Dis. 2018 Sep;18(9):936-937. doi: 10.1016/S1473-3099(18)30308-6. Epub 2018 Jul 17. No abstract available.

PMID:
30025912
14.

High rate of Clostridium difficile among young adults presenting with diarrhea at two hospitals in Kenya.

Oyaro MO, Plants-Paris K, Bishoff D, Malonza P, Gontier CS, DuPont HL, Darkoh C.

Int J Infect Dis. 2018 Sep;74:24-28. doi: 10.1016/j.ijid.2018.06.014. Epub 2018 Jun 28.

15.

New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.

Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J.

Dig Liver Dis. 2018 Aug;50(8):741-749. doi: 10.1016/j.dld.2018.04.020. Epub 2018 Apr 27. Review.

PMID:
29807873
16.

Gastric Acid and Enteric Infections: Souring on the Use of PPIs.

DuPont HL.

Dig Dis Sci. 2018 Apr;63(4):814-817. doi: 10.1007/s10620-018-4955-1. No abstract available.

PMID:
29427223
17.

Erratum for Darkoh et al., "Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile".

Darkoh C, Odo C, DuPont HL.

MBio. 2017 Oct 31;8(5). pii: e01643-17. doi: 10.1128/mBio.01643-17. No abstract available.

18.

Comment: Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin.

DuPont HL, Bajaj JS.

Ann Pharmacother. 2018 Jan;52(1):94-95. doi: 10.1177/1060028017738263. Epub 2017 Oct 25. No abstract available.

PMID:
29068235
19.

Clinical features and molecular epidemiology of diarrheagenic Escherichia coli pathotypes identified by fecal gastrointestinal multiplex nucleic acid amplification in patients with cancer and diarrhea.

Chao AW, Bhatti M, DuPont HL, Nataro JP, Carlin LG, Okhuysen PC.

Diagn Microbiol Infect Dis. 2017 Nov;89(3):235-240. doi: 10.1016/j.diagmicrobio.2017.08.004. Epub 2017 Aug 12.

PMID:
28931467
21.

Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI).

Jiang ZD, Alexander A, Ke S, Valilis EM, Hu S, Li B, DuPont HL.

Anaerobe. 2017 Dec;48:110-114. doi: 10.1016/j.anaerobe.2017.08.003. Epub 2017 Aug 9.

PMID:
28801119
22.

Nonantimicrobial drug targets for Clostridium difficile infections.

Darkoh C, Deaton M, DuPont HL.

Future Microbiol. 2017 Sep;12:975-985. doi: 10.2217/fmb-2017-0024. Epub 2017 Jul 31.

23.

Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Riddle MS, Connor BA, Beeching NJ, DuPont HL, Hamer DH, Kozarsky P, Libman M, Steffen R, Taylor D, Tribble DR, Vila J, Zanger P, Ericsson CD.

J Travel Med. 2017 Apr 1;24(suppl_1):S57-S74. doi: 10.1093/jtm/tax026. Review.

24.

Etiology of travellers' diarrhea.

Jiang ZD, DuPont HL.

J Travel Med. 2017 Apr 1;24(suppl_1):S13-S16. doi: 10.1093/jtm/tax003. Review.

PMID:
28521001
25.

The accessory gene regulator-1 as a therapeutic target for C. difficile infections.

Darkoh C, DuPont HL.

Expert Opin Ther Targets. 2017 May;21(5):451-453. doi: 10.1080/14728222.2017.1311863. Epub 2017 Apr 3. No abstract available.

26.

Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy.

Jiang ZD, Ajami NJ, Petrosino JF, Jun G, Hanis CL, Shah M, Hochman L, Ankoma-Sey V, DuPont AW, Wong MC, Alexander A, Ke S, DuPont HL.

Aliment Pharmacol Ther. 2017 Apr;45(7):899-908. doi: 10.1111/apt.13969. Epub 2017 Feb 21.

27.

Emerging Infectious Diseases, Animals, and Future Epidemics.

DuPont HL.

Tex Med. 2017 Feb 1;113(2):31-36. Review.

PMID:
28207078
28.

Colonization Factors in Enterotoxigenic Escherichia coli Strains in Travelers to Mexico, Guatemala, and India Compared with Children in Houston, Texas.

Kharat VB, Ahmed M, Jiang ZD, Riddle MS, DuPont HL.

Am J Trop Med Hyg. 2017 Jan 11;96(1):83-87. doi: 10.4269/ajtmh.16-0405. Epub 2016 Nov 14.

29.

Management of Clostridium difficile Infection.

Al-Jashaami LS, DuPont HL.

Gastroenterol Hepatol (N Y). 2016 Oct;12(10):609-616.

30.

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.

DuPont HL, Wolf RA, Israel RJ, Pimentel M.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e02165-16. doi: 10.1128/AAC.02165-16. Print 2017 Jan. No abstract available.

31.

Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile.

Darkoh C, Odo C, DuPont HL.

MBio. 2016 Aug 16;7(4). pii: e01237-16. doi: 10.1128/mBio.01237-16. Erratum in: MBio. 2017 Oct 31;8(5):.

33.

Persistent Diarrhea: A Clinical Review.

DuPont HL.

JAMA. 2016 Jun 28;315(24):2712-23. doi: 10.1001/jama.2016.7833. Review.

PMID:
27357241
34.

Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.

Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, Xie Y, DuPont HL, Garey KW.

J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20.

PMID:
27209056
35.

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults.

Riddle MS, DuPont HL, Connor BA.

Am J Gastroenterol. 2016 May;111(5):602-22. doi: 10.1038/ajg.2016.126. Epub 2016 Apr 12.

PMID:
27068718
36.

Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire.

Garey KW, Aitken SL, Gschwind L, Goddu S, Xie Y, Duff C, Barbut F, Shah DN, DuPont HL.

J Clin Gastroenterol. 2016 Sep;50(8):631-7. doi: 10.1097/MCG.0000000000000473.

37.

Review article: the antimicrobial effects of rifaximin on the gut microbiota.

DuPont HL.

Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:3-10. doi: 10.1111/apt.13434. Review.

38.

Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.

DuPont HL.

Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:1-2. doi: 10.1111/apt.13406.

39.

Rifaximin: An Antibiotic with Important Biologic Effects.

DuPont HL.

Mini Rev Med Chem. 2015;16(3):200-5. Review.

PMID:
26202192
40.

Risk Factors for Community-associated Clostridium difficile-associated Diarrhea in Children.

Crews JD, Anderson LR, Waller DK, Swartz MD, DuPont HL, Starke JR.

Pediatr Infect Dis J. 2015 Sep;34(9):919-23. doi: 10.1097/INF.0000000000000767.

41.

Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases.

DuPont HL.

Mayo Clin Proc. 2015 Aug;90(8):1116-24. doi: 10.1016/j.mayocp.2015.04.016. Epub 2015 Jul 8. Review.

PMID:
26162610
42.

New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics.

Patel R, DuPont HL.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S108-21. doi: 10.1093/cid/civ177. Review.

43.

Toxin synthesis by Clostridium difficile is regulated through quorum signaling.

Darkoh C, DuPont HL, Norris SJ, Kaplan HB.

MBio. 2015 Feb 24;6(2):e02569. doi: 10.1128/mBio.02569-14.

44.

Characterization of the human gut microbiome during travelers' diarrhea.

Youmans BP, Ajami NJ, Jiang ZD, Campbell F, Wadsworth WD, Petrosino JF, DuPont HL, Highlander SK.

Gut Microbes. 2015;6(2):110-9. doi: 10.1080/19490976.2015.1019693.

45.

Loperamide therapy for voluminous diarrhea in Ebola virus disease.

Chertow DS, Uyeki TM, DuPont HL.

J Infect Dis. 2015 Apr 1;211(7):1036-7. doi: 10.1093/infdis/jiv001. Epub 2015 Jan 8. No abstract available.

46.

JAMA patient page. Traveler's diarrhea.

Steffen R, Hill DR, DuPont HL.

JAMA. 2015 Jan 6;313(1):108. doi: 10.1001/jama.2014.17152. No abstract available.

PMID:
25562284
47.

Traveler's diarrhea: a clinical review.

Steffen R, Hill DR, DuPont HL.

JAMA. 2015 Jan 6;313(1):71-80. doi: 10.1001/jama.2014.17006. Review.

PMID:
25562268
48.

A hospital-based study of the clinical characteristics of Clostridium difficile infection in children.

Crews JD, Koo HL, Jiang ZD, Starke JR, DuPont HL.

Pediatr Infect Dis J. 2014 Sep;33(9):924-8. doi: 10.1097/INF.0000000000000338.

49.

Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.

DuPont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG, Ballard ED, Totoritis MC.

J Travel Med. 2014 Nov-Dec;21(6):369-76. doi: 10.1111/jtm.12168.

50.

Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas.

Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW.

PLoS One. 2014 Jul 24;9(7):e102848. doi: 10.1371/journal.pone.0102848. eCollection 2014.

Supplemental Content

Loading ...
Support Center